Best of ASCO® Toronto 2024: Non-Prostate GU Cancer – Dr. Eric Winquist
OR
Co-Chairs
Dr. Aly-Khan Lalani
Dr. Natasha Leighl
Speakers
Dr. Eric Winquist
Studies/trials discussed:
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
- Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)
- Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
